Patients with advanced melanoma lacking the BRAF mutation face limited treatment options once they no longer respond to immune checkpoint inhibitors (ICIs). A promising new study conducted by researchers at Vanderbilt University, led by Professor Emerita of Pharmacology Ann Richmond, introduces a transformative therapeutic strategy aimed at re-sensitizing resistant tumors to immunotherapy.
The study reveals a three-drug combination that enhances immune activity while suppressing tumor-promoting immune cells. By utilizing a low dose of the MEK inhibitor trametinib, the multi-kinase inhibitor rigosertib, and a CD40 agonist, researchers are able to shift the tumor microenvironment towards immune activation. Importantly, all three agents have either received approval from the U.S. Food and Drug Administration or are currently undergoing clinical trials, potentially accelerating their availability for patient testing.
Combating Immune Suppression
While therapies that activate CD40 can be beneficial in treating melanoma, they also inadvertently promote the development of CD11b + B regulatory cells, which hinder T cell responses to tumors. Richmond noted, “We showed that combining CD40 therapy with trametinib and rigosertib prevents the induction of these B regulatory cells.”
ICIs have become a cornerstone in melanoma therapy by releasing the molecular “brakes” that inhibit T cells from attacking cancer. Yet, resistance to these treatments is prevalent in metastatic melanoma, particularly in tumors that evolve immune-suppressive environments. The study highlights that while CD40 agonists activate immune cells, they also lead to an expansion of regulatory B cells. By integrating CD40 activation with MEK and PI3K inhibition, the researchers effectively blocked the expansion of these suppressive B cells while preserving the advantages of CD40 stimulation.
In preclinical mouse models of melanoma, the triple-drug combination not only suppressed tumor growth but also restored responsiveness to checkpoint blockade.
Key Findings and Future Implications
The study identified two primary findings:
1. **B Cells as a Resistance Mechanism**: The use of CD40 therapy alone resulted in the induction of regulatory B cells, which dampen T cell-mediated tumor immunity.
2. **Triple Combination Prevents Immune Suppression**: Co-treatment with trametinib and rigosertib inhibited the CD40 agonist’s induction of regulatory B cells, allowing for unimpeded immune responses.
The combination therapy has shown the potential to slow tumor progression and re-sensitize resistant melanomas to anti-PD-1 therapy. This approach offers a new avenue for enhancing antitumor immunity in patients whose tumors have become unresponsive to existing immunotherapies.
Richmond’s team expresses optimism about the rapid translation of this research into clinical trials for melanoma patients who have progressed on ICIs. “This approach provides a new route to enhance antitumor immunity in patients with tumors that no longer respond to immunotherapy,” said Richmond.
The project was a collaborative effort involving fellow Vanderbilt principal investigators Vivian Weiss, Doug Johnson, and Qi Liu. The first author of the paper, former Research Assistant Professor of Pharmacology Chi Yan, will continue this research in his new lab at the University of Manitoba.
The study titled “RAS/MEK/PI3K pathway inhibition augments response to CD40 agonism by targeting CD11b + Bregs thereby overcoming melanoma PD1-resistance” was published in Nature Communications in January 2026. Funding was provided by the National Cancer Institute, the Department of Veterans Affairs, and a Lloyd Foundation Melanoma Research Grant.
This research was made available through an open-access publication, ensuring immediate and unrestricted access to findings worldwide, a significant step towards enhancing the dissemination of scientific knowledge.
